This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arnold, G. F.
Right arrow Articles by Arnold, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, G. F.
Right arrow Articles by Arnold, E.

 Previous Article  |  Next Article 

Journal of Virology, May 2009, p. 5087-5100, Vol. 83, No. 10
0022-538X/09/$08.00+0     doi:10.1128/JVI.00184-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Broad Neutralization of Human Immunodeficiency Virus Type 1 (HIV-1) Elicited from Human Rhinoviruses That Display the HIV-1 gp41 ELDKWA Epitope{triangledown} ,{dagger}

Gail Ferstandig Arnold,1,2,3* Paola K. Velasco,1,2,3 Andrew K. Holmes,1,2,3 Terri Wrin,4 Sheila C. Geisler,1,2 Pham Phung,4 Yu Tian,2,{ddagger} Dawn A. Resnick,1,2 Xuejun Ma,1,2 Thomas M. Mariano,1,2 Christos J. Petropoulos,4 John W. Taylor,2 Hermann Katinger,5 and Eddy Arnold1,2,3*

Center for Advanced Biotechnology and Medicine, Piscataway, New Jersey,1 Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey,2 Rutgers University—University of Medicine and Dentistry of New Jersey Molecular Biosciences Graduate Program, Piscataway, New Jersey,3 Monogram Biosciences, Inc., South San Francisco, California,4 Institute of Applied Microbiology, University of Agriculture, Vienna, Austria5

Received 26 January 2009/ Accepted 23 February 2009

In efforts to develop AIDS vaccine components, we generated combinatorial libraries of recombinant human rhinoviruses that display the well-conserved ELDKWA epitope of the membrane-proximal external region of human immunodeficiency virus type 1 (HIV-1) gp41. The broadly neutralizing human monoclonal antibody 2F5 was used to select for viruses whose ELDKWA conformations resemble those of HIV. Immunization of guinea pigs with different chimeras, some boosted with ELDKWA-based peptides, elicited antibodies capable of neutralizing HIV-1 pseudoviruses of diverse subtypes and coreceptor usages. These recombinant immunogens are the first reported that elicit broad, albeit modest, neutralization of HIV-1 using an ELDKWA-based epitope and are among the few reported that elicit broad neutralization directed against any recombinant HIV epitope, providing a critical advance in developing effective AIDS vaccine components.


* Corresponding author. Mailing address: Center for Advanced Biotechnology and Medicine, 679 Hoes Lane, Piscataway, NJ 08854-5638. Phone for G. F. Arnold: (732) 235-4343. Fax: 732-235-5788. E-mail: gfarnold{at}cabm.rutgers.edu. Phone for E. Arnold: (732) 235-5323. E-mail: arnold{at}cabm.rutgers.edu

{triangledown} Published ahead of print on 11 March 2009.

{dagger} Supplemental material for this article may be found at http://jvi.asm.org/.

{ddagger} Present address: Abbott Laboratories, Bedford, MA.


Journal of Virology, May 2009, p. 5087-5100, Vol. 83, No. 10
0022-538X/09/$08.00+0     doi:10.1128/JVI.00184-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Bryson, S., Julien, J.-P., Hynes, R. C., Pai, E. F. (2009). Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications. J. Virol. 83: 11862-11875 [Abstract] [Full Text]